Frank Rahmani

Feb 27, 2024 | lexology.com | Sharon Flanagan |Stephen Abreu |Robert Darwin |Carlton Fleming |Frank Rahmani |Meenakshi Datta | +3 more

Our lawyers share the top investment and regulatory trends from last month’s agenda-setting JP Morgan Health Care Conference. We expect an abundance of novel financing structures, investment focus on new disease states, and important new U.S. Food and Drug Administration (FDA) guidance. Regulatory developments in the U.S.: The FDA has issued several new policy documents on issues such as clinical trial design and conduct, affirming the agency’s high bar for approvals.